<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384186</url>
  </required_header>
  <id_info>
    <org_study_id>ACH471-011</org_study_id>
    <secondary_id>2017-003525-15</secondary_id>
    <nct_id>NCT03384186</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic (PK) Study of ACH-0144471 Modified Release Prototype Formulations in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achillion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Achillion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the plasma PK profiles of study drug,
      ACH-0144471, in healthy subjects after administration of a single dose of multiple
      ACH-0144471 prototype formulations given by mouth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">March 28, 2018</completion_date>
  <primary_completion_date type="Actual">February 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) measures: Time to maximum concentration (Tmax)</measure>
    <time_frame>Plasma samples for PK will be taken pre-dose to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) measures: Maximum observed concentration (Cmax)</measure>
    <time_frame>Plasma samples for PK will be taken pre-dose to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) measures: Area Under the Curve (AUC)</measure>
    <time_frame>Plasma samples for PK will be taken pre-dose to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) measures: Frel (relative bioavailability)</measure>
    <time_frame>Plasma samples for PK will be taken pre-dose to 72 hours post-dose</time_frame>
    <description>MR prototypes 2 to 5 [test] versus MR Prototype 1 [reference]; fed versus fasted, if required</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of participants with Serious Adverse Events (SAEs), Treatment Emergent Adverse Events (TEAEs), and TEAEs leading to discontinuation</measure>
    <time_frame>Screening through 28 days following the last dose of study drug</time_frame>
    <description>(Abnormalities in safety laboratory tests, vital signs, ECGs, physical examination that meet the protocol definition will be captured as AEs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ACH-0144471 Modified Release Prototypes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471 Modified Release Prototype 1</intervention_name>
    <description>400 mg ACH-0144471 Modified Release Prototype 1 in the fasted state</description>
    <arm_group_label>ACH-0144471 Modified Release Prototypes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471 Modified Release Prototype 2</intervention_name>
    <description>XXX mg ACH-0144471 Modified Release Prototype 2 in the fasted state</description>
    <arm_group_label>ACH-0144471 Modified Release Prototypes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471 Modified Release Prototype 3</intervention_name>
    <description>XXX mg ACH-0144471 Modified Release Prototype 3 in the fasted state</description>
    <arm_group_label>ACH-0144471 Modified Release Prototypes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471 Modified Release Prototype 4</intervention_name>
    <description>XXX mg ACH-0144471 Modified Release Prototype 4 in the fasted state, or a prior MR Prototype in the fed state (optional period)</description>
    <arm_group_label>ACH-0144471 Modified Release Prototypes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACH-0144471 Modified Release Prototype 5</intervention_name>
    <description>XXX mg ACH-0144471 Modified Release Prototype 5 in the fasted state, or a prior MR Prototype in the fed state (optional period)</description>
    <arm_group_label>ACH-0144471 Modified Release Prototypes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index of 18.0 to 30.0 kg/m2

          -  Must be willing and able to communicate and participate in the whole study

          -  Must provide written informed consent

          -  Female subjects of childbearing potential must either agree to abstinence or to use,
             with their partner, a highly effective method of contraception from screening until 30
             days after the last follow-up visit.

          -  Male subjects must either agree to abstinence or to use, with their partner, a condom
             plus an effective method of contraception throughout the dosing period and for at
             least 14 days after study discharge. Males must agree to not donate sperm throughout
             the dosing period and for at least 14 days after study discharge.

        Exclusion Criteria:

          -  Subjects who have received any IMP in a clinical research study within the previous 3
             months

          -  Subjects who are study site employees, or immediate family members of a study site or
             sponsor employee

          -  Subjects who have previously been enrolled in this study.

          -  History of any drug or alcohol abuse in the past 2 years

          -  Current smokers and those who have smoked within the last 12 months.

          -  Current users of e-cigarettes and nicotine replacement products and those who have
             used these products within the last 12 months

          -  Females of childbearing potential who are pregnant or lactating

          -  Clinically significant laboratory abnormalities

          -  Clinically significant vital sign or ECG abnormalities

          -  Positive drugs of abuse test result

          -  Positive test for HIV, Hepatitis B and/or C

          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or GI disease, neurological or psychiatric disorder

          -  History or family history of meningococcal infection

          -  History of cholecystectomy or gallstones

          -  History of sensitivity to study drug

          -  Presence or history of clinically significant allergy requiring treatment

          -  Donation or loss of greater than 400 mL of blood within the previous 3 months

          -  Use of prescription medications within 14 days of first dose

          -  Use of medications known to induce hepatic microsomal enzyme CYP activity within 28
             days of first dose

          -  Prior history or current evidence of biliary cholestasis

          -  Have of history of Gilbert's syndrome

          -  Male subjects with a female partner who is pregnant, nursing, or planning to become
             pregnant during the study or within 14 days after study discharge

        NOTE: Other inclusion/exclusion criteria may apply, per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharan Sidhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Sciences Ltd.</name>
      <address>
        <city>Ruddington</city>
        <state>Nottingham</state>
        <zip>NG111 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

